MyFinsight
Home
Blog
About
Proceeds from exercise of
options and espp...
$8,302K
(90.76%↑ Y/Y)
Net cash provided by
financing activities
$7,180K
(-44.11%↓ Y/Y)
Effect of exchange rate
changes on cash
$6K
(-95.04%↓ Y/Y)
Canceled cashflow
$1,122K
Decrease in cash
-$131,971K
(-26.12%↓ Y/Y)
Canceled cashflow
$7,186K
Equity-based compensation
$17,316K
(-54.21%↓ Y/Y)
Depreciation and
amortization
$4,280K
(-54.40%↓ Y/Y)
Other liabilities,
net
$4,147K
(141.07%↑ Y/Y)
Acquired in-process
research and development
$2,473K
(-97.43%↓ Y/Y)
Amortization of debt issuance
costs
$848K
Sales of marketable
securities
$170,995K
Issuance costs and
discounts associated with...
$1,122K
Net cash used in
operating activities
-$83,498K
(50.25%↑ Y/Y)
Net cash (used in)
provided by investing...
-$55,659K
(-210.83%↓ Y/Y)
Canceled cashflow
$29,064K
Canceled cashflow
$170,995K
Net loss
-$91,154K
(73.54%↑ Y/Y)
Purchases of marketable
securities
$206,299K
(-49.82%↓ Y/Y)
Other non-cash items,
net
$13,563K
(167.25%↑ Y/Y)
Accounts payable and
accrued expenses
-$5,306K
(-118.75%↓ Y/Y)
Operating lease assets and
liabilities
-$1,543K
(36.27%↑ Y/Y)
Prepaid expenses and
other assets
$841K
(15.68%↑ Y/Y)
Deferred revenue
-$155K
(90.97%↑ Y/Y)
Investment in equity
securities
$8,728K
(-10.02%↓ Y/Y)
Maturities of marketable
securities
-$8,506K
(-101.71%↓ Y/Y)
Purchases of in-process
research and development
$2,473K
(-90.11%↓ Y/Y)
Purchases of property,
plant and equipment
$648K
(100.62%↑ Y/Y)
Back
Back
Cash Flow
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)
source: myfinsight.com